Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
OKYO Pharma Limited Sponsored ADR ( (OKYO) ) has issued an update.
On January 5, 2026, OKYO Pharma appointed ophthalmology industry veteran Robert J. Dempsey as Chief Executive Officer and an executive board member, while former CEO Gary S. Jacob, Ph.D., moved into the role of Chief Development Officer and remained on the board. The board-approved leadership transition, effective immediately, is designed to maintain strategic continuity while sharpening OKYO’s commercial and development focus as it advances its flagship drug urcosimod for neuropathic corneal pain and other ocular inflammatory disorders; Dempsey’s track record in launching and commercializing blockbuster eye therapies such as Xiidra and Restasis is expected to strengthen OKYO’s positioning in the ophthalmology market and support the company’s next phase of growth around its planned larger Phase 2 NCP program.
The most recent analyst rating on (OKYO) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on OKYO Pharma Limited Sponsored ADR stock, see the OKYO Stock Forecast page.
Spark’s Take on OKYO Stock
According to Spark, TipRanks’ AI Analyst, OKYO is a Neutral.
The score is constrained primarily by weak financial fundamentals (pre-revenue operations, continued losses, negative equity) despite improving cost control and no debt. Technical indicators add modest downside pressure (below key moving averages and negative MACD), while valuation provides limited support due to a negative P/E and no dividend.
To see Spark’s full report on OKYO stock, click here.
More about OKYO Pharma Limited Sponsored ADR
OKYO Pharma Limited is a clinical-stage biopharmaceutical company listed on the NASDAQ Capital Market, focused on developing innovative therapies for neuropathic corneal pain (NCP) and inflammatory eye diseases. Its lead asset, urcosimod, a chemerin peptide agonist targeting ChemR23, has shown anti-inflammatory and pain-reducing activity in preclinical models and achieved statistically significant results in a Phase 2 trial in dry eye disease, as well as positive pain reduction data in a Phase 2 trial in NCP, with a larger multicenter NCP trial planned to start in the first quarter of 2026.
Average Trading Volume: 147,747
Technical Sentiment Signal: Buy
Current Market Cap: $83.87M
See more insights into OKYO stock on TipRanks’ Stock Analysis page.